BioNTech has struck a deal to explore oral delivery of mRNA vaccines. Working with Matinas BioPharma, the German mRNA specialist will study the potential for a lipid nanocrystal (LNC) platform to enable new vaccine formulations.
The pandemic catapulted BioNTech into the biotech big leagues as the vaccine it discovered and then developed with Pfizer became a cornerstone of vaccination COVID-19 campaigns around the world. From that position of strength, BioNTech has identified Matinas as a company that can help it build a business beyond the Comirnaty windfall.
